Disease/Infection News

RSS

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that it has entered into a Cooperative Research and Development Agreement ("CRADA") with The Walter Reed Army Institute of Research.

2 Nov 2010

Inhibitex to present INX-189 data for HCV infections at AASLD Meeting

Inhibitex, Inc. announced today that three posters describing preclinical data on INX-189, the Company's nucleotide polymerase inhibitor in clinical development for the treatment of chronic hepatitis C (HCV) infections, will be presented by various scientists from the Company at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA.

2 Nov 2010

VaxInnate’s prototype flu vaccine named as Top 10 Infectious Diseases Projects to Watch in 2011

VaxInnate Corporation announced today that VAX125, its investigational prototype vaccine for seasonal flu, has been named one of the Top 10 Infectious Diseases Projects to Watch in 2011 by Elsevier Business Intelligence and the Windhover Conferences.

2 Nov 2010

Vacuum cleaner with UV technology effective at reducing carpet's surface microbes

New research suggests that the addition of ultraviolet light to the brushing and suction of a vacuum cleaner can almost double the removal of potentially infectious microorganisms from a carpet's surface when compared to vacuuming alone.

2 Nov 2010

ADVANCE Phase 3 study confirms clinical benefits of telaprevir regimen in patients with HCV infection

The Phase 3 results from the ADVANCE study confirm the clinical benefits of telaprevir-based combination therapy regimens. The study reports an improvement in treatment discontinuation rates due to adverse events compared to Phase 2 studies, and demonstrates an increase in sustained viral response (SVR) in patients with hepatitis C virus (HCV). The primary endpoint for this study was SVR 24 weeks after last treatment.

2 Nov 2010

Boceprevir combinational therapy improves SVR rate in patients with HCV genotype 1

The final results of the RESPOND-2 trial demonstrated that combination therapy with Boceprevir yields higher sustained virologic response (SVR) rates for patients with hepatitis C virus (HCV) genotype 1 who did not respond to or relapsed after treatment with peginterferon alpha 2b and Ribavirin.

2 Nov 2010

PPACA program provides $733,438 grant to Inovio

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has received a $733,438 grant under The Patient Protection and Affordable Care Act of 2010 (PPACA).

2 Nov 2010

Kenya first of four countries to launch UNICEF, partners initiative aimed at PMTCT of HIV

On Friday, UNICEF and the Kenyan government announced a partnership aimed at preventing mother-to-child transmission (PMTCT) of HIV by providing HIV-positive mothers with packs of medicines they can easily administer to themselves or their babies at home, IRIN/PlusNews reports.

2 Nov 2010

AGD encourages diabetic patients to pay attention to oral health

According to the U.S. Centers for Disease Control and Prevention, diabetes affects nearly 24 million people in the United States. In observance of National Diabetes Month, the Academy of General Dentistry (AGD) encourages those with diabetes to pay extra attention to their oral health.

2 Nov 2010

WHO Director-General in Pakistan to monitor flood relief, polio vaccinations

The WHO will continue to support efforts to boost polio eradication efforts in Pakistan, WHO Director-General Margaret Chan said recently during talks with Pakistani health officials, the Associated Press of Pakistan reports.

2 Nov 2010

White House Health Advisor Emanuel visits U.S. government-funded health programs during 3-nation African trip

The global fight against malaria could cut prevalence rates of malaria to one in 20 fevers by 2017, Special Advisor on Health Policy to the Director of the White House Office of Management and Budget Ezekiel Emanuel said in an interview in Dakar, Senegal, Bloomberg reports.

2 Nov 2010

IRIN examines debate over malaria control versus eradication

After the recent publication of the Lancet series on malaria eradication, IRIN examines the debate over control versus eradication, stating the findings of some of the studies.

2 Nov 2010

H. pylori infection reduces severity of Salmonella-induced colitis: Research

Helicobacter pylori, a common stomach bacterium, reduced the severity of inflammation of the colon caused by Salmonella in mice, according to research from U-M Medical School scientists.

2 Nov 2010

Valeant, Kadmon enter strategic agreement for taribavirin and ribavirin

Valeant Pharmaceuticals International, Inc. and Kadmon Pharmaceuticals LLC have concluded two strategic agreements for the development and commercialization of taribavirin and the commercial marketing of ribavirin in the treatment of viral diseases, including hepatitis C virus (HCV).

1 Nov 2010

Lab study shows nanoviricide drug candidate improves survival rate in influenza viral infection

NanoViricides, Inc. reported today that its FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of influenza virus. Animals treated with all of the different influenza nanoviricide drug candidates survived for dramatically longer periods as compared to Tamiflu treated animals.

1 Nov 2010

Medicago receives Health Canada clearance for Phase II clinical trial of H5N1 Avian Influenza vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has received clearance from Health Canada to commence a Phase II human clinical trial with its H5N1 Avian Influenza vaccine ("H5N1 vaccine"). Enrolment of volunteers is now underway.

1 Nov 2010

Inhibitex announces initiation of INX-189 Phase 1b clinical trial for HCV infection

Inhibitex, Inc. announced today that it has initiated a Phase 1b, multiple ascending dose (MAD) clinical trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic infections caused by hepatitis C virus (HCV).

1 Nov 2010

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Vertex Pharmaceuticals Incorporated today announced new data from its Phase 3 studies of people with genotype 1 chronic hepatitis C who have not been treated previously. In these studies, the majority of people achieved superior sustained viral response (SVR or viral cure) rates with a telaprevir-based combination regimen, compared to current therapies, regardless of race/ethnicity or stage of liver fibrosis (factors known to limit response to current hepatitis C treatments).

1 Nov 2010

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced the results of a Week-24 planned interim analysis of the Phase 2 response-guided PILLAR study for TMC435, Medivir's key pipeline asset, a hepatitis C protease inhibitor dosed once-daily.

1 Nov 2010

Merck's boceprevir improves SVR rate in adults with chronic hepatitis C virus genotype 1 infection

Merck reported today that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, demonstrated significantly higher sustained virologic response (SVR) rates in adult patients who previously failed treatment (treatment-failure; HCV RESPOND-2) and in adult patients who were new to treatment for chronic hepatitis C virus (HCV) genotype 1 compared to control, the primary objective of the studies.

1 Nov 2010

Disease/Infection News

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

Inhibitex to present INX-189 data for HCV infections at AASLD Meeting

VaxInnate’s prototype flu vaccine named as Top 10 Infectious Diseases Projects to Watch in 2011

Vacuum cleaner with UV technology effective at reducing carpet's surface microbes

ADVANCE Phase 3 study confirms clinical benefits of telaprevir regimen in patients with HCV infection

Boceprevir combinational therapy improves SVR rate in patients with HCV genotype 1

PPACA program provides $733,438 grant to Inovio

Kenya first of four countries to launch UNICEF, partners initiative aimed at PMTCT of HIV

AGD encourages diabetic patients to pay attention to oral health

WHO Director-General in Pakistan to monitor flood relief, polio vaccinations

White House Health Advisor Emanuel visits U.S. government-funded health programs during 3-nation African trip

IRIN examines debate over malaria control versus eradication

H. pylori infection reduces severity of Salmonella-induced colitis: Research

Valeant, Kadmon enter strategic agreement for taribavirin and ribavirin

Lab study shows nanoviricide drug candidate improves survival rate in influenza viral infection

Medicago receives Health Canada clearance for Phase II clinical trial of H5N1 Avian Influenza vaccine

Inhibitex announces initiation of INX-189 Phase 1b clinical trial for HCV infection

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

Merck's boceprevir improves SVR rate in adults with chronic hepatitis C virus genotype 1 infection

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News